Join
Live feed
·
PRReleasevia Quantisnow
Septerna Inc. logo

Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism

ByQuantisnow·Wall Street's wire, on your screen.
SEPN· Septerna Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SEPN (Septerna Inc.) and more on Quantisnow.